{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["van Harten AM"],"funding":["The study was supported by VUmc Cancer Center Amsterdam and Amsterdam UMC."],"pubmed_abstract":["Head and neck squamous cell carcinomas (HNSCCs) coincide with poor survival rates. The lack of driver oncogenes complicates the development of targeted treatments for HNSCC. Here, we follow-up on two previous genome-wide RNA and microRNA interference screens in HNSCC to cross-examine tumor-specific lethality by targeting ATM, ATR, CHEK1, or CHEK2. Our results uncover CHEK1 as the most promising target for HNSCC. CHEK1 expression is essential across a panel of HNSCC cell lines but redundant for growth and survival of untransformed oral keratinocytes and fibroblasts. LY2603618 (Rabusertib), which specifically targets Chk1 kinase, kills HNSCC cells effectively and specifically. Our findings show that HNSCC cells depend on Chk1-mediated signaling to progress through S-phase successfully. Chk1 "],"journal":["Oncogenesis"],"pagination":["38"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6572811"],"repository":["biostudies-literature"],"pubmed_title":["Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death."],"pmcid":["PMC6572811"],"pubmed_authors":["Brakenhoff RH","Rooimans MA","van Harten AM","van der Mast R","Bachas C","Brink A","Wolthuis RMF","Buijze M","Martens-de Kemp SR","Stigter-van Walsum M"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death.","description":"Head and neck squamous cell carcinomas (HNSCCs) coincide with poor survival rates. The lack of driver oncogenes complicates the development of targeted treatments for HNSCC. Here, we follow-up on two previous genome-wide RNA and microRNA interference screens in HNSCC to cross-examine tumor-specific lethality by targeting ATM, ATR, CHEK1, or CHEK2. Our results uncover CHEK1 as the most promising target for HNSCC. CHEK1 expression is essential across a panel of HNSCC cell lines but redundant for growth and survival of untransformed oral keratinocytes and fibroblasts. LY2603618 (Rabusertib), which specifically targets Chk1 kinase, kills HNSCC cells effectively and specifically. Our findings show that HNSCC cells depend on Chk1-mediated signaling to progress through S-phase successfully. Chk1 ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2026-05-01T04:40:17.127Z","creation":"2025-05-31T22:25:57.581Z"},"accession":"S-EPMC6572811","cross_references":{"pubmed":["31209198"],"doi":["10.1038/s41389-019-0147-x"]}}